Fig. 8
From: Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma
Primary patient tumors tested ex vivo for synergy. ECs were exposed to rucaparib, SN-38, or the combination at titrating concentrations. A) Six drug dilutions were used to generate the combination index (CI) curves using Calcusyn. B) The CI values at 0.5 fraction of cells affected (Fa) are plotted from panel A by histology: serous, endometrioid (EM), and carcinosarcoma (CSC). P53 aberrant ( ● ) and wildtype ( □ ) tumors are indicated